You can now read 5 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

OvaScience secures $37m in Series B financing

OvaScience, a Cambridge company specializing in fertility treatments, announced Wednesday that it has completed a $37 million Series B financing.

The financing was led by General Catalyst. Existing investors, Bessemer Venture Partners and Longwood Fund, were joined by new investors BBT Capital Management Advisors, LLC, Cycad Group, Hunt BioVentures, and RA Capital, among others. Leerink Swann LLC acted as lead placement agent for the offering.

Continue reading below

In a press release, OvaScience said it plans to use the proceeds from the financing to support the development and commercialization of its fertility treatment approaches based on the egg precursor cell discoveries of OvaScience cofounder Jonathan Tilly.

Tilly is director of the Vincent Center for Reproductive Biology and chief of research for Massachusetts General Hospital’s Vincent Department of Obstetrics and Gynecology. He is also a professor at the Harvard Medical School.

Chris Reidy can be reached at
Loading comments...

Wake up with today's top stories.

Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
Please enter a valid email will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of